Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

Exclusion Criteria

• •Subject has a concurrent disease or condition that, in the opinion of the investigator, would interfere with continued study participation or confound the evaluation of safety and tolerability of the study drug.
• •Subject has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergics.
• •Subject suffers from any medical condition that would preclude the use of inhaled anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic hyperplasia, bladder neck obstruction, or urinary retention.